My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 1032

    1.

    Immune correlates of CD4 decline in HIV-infected patients experiencing virologic failure before undergoing treatment interruption.

    Huang KH, Loutfy MR, Tsoukas CM, Bernard NF.

    BMC Infect Dis. 2008 May 2;8:59.PMID: 18454861 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Predictive value of immune parameters before treatment interruption (TI) for CD4+ T-cell count change during TI in HIV infection.

    Huang KH, Loutfy MR, Boulet S, Toma E, Tsoukas CM, Bernard NF.

    Antivir Ther. 2009;14(3):381-92.PMID: 19474472 [PubMed - indexed for MEDLINE]Related articles

    3.

    Predictors of sustained response to therapy resumption after treatment interruption in HIV-infected patients failing antiretroviral therapy.

    Gianotti N, Soria A, Galli L, Castagna A, Cernuschi M, Hasson H, Lazzarin A.

    J Med Virol. 2004 Feb;72(2):181-6.PMID: 14695657 [PubMed - indexed for MEDLINE]Related articles

    4.

    A pilot study evaluating time to CD4 T-cell count <350 cells/mm(3) after treatment interruption following antiretroviral therapy +/- interleukin 2: results of ACTG A5102.

    Henry K, Katzenstein D, Cherng DW, Valdez H, Powderly W, Vargas MB, Jahed NC, Jacobson JM, Myers LS, Schmitz JL, Winters M, Tebas P; A5102 Study Team of the AIDS Clinical Trials Group.

    J Acquir Immune Defic Syndr. 2006 Jun;42(2):140-8.PMID: 16760795 [PubMed - indexed for MEDLINE]Related articles

    5.

    Three-year immune reconstitution in PI-sparing and PI-containing antiretroviral regimens in advanced HIV-1 disease.

    Samri A, Goodall R, Burton C, Imami N, Pantaleo G, Kelleher A, Poli G, Gotch F, Autran B.

    Antivir Ther. 2007;12(4):553-8.PMID: 17668564 [PubMed - indexed for MEDLINE]Related articles

    6.

    Persistent low viral load on antiretroviral therapy is associated with T cell-mediated control of HIV replication.

    Alatrakchi N, Duvivier C, Costagliola D, Samri A, Marcelin AG, Kamkamidze G, Astriti M, Agher R, Calvez V, Autran B, Katlama C.

    AIDS. 2005 Jan 3;19(1):25-33.PMID: 15627030 [PubMed - indexed for MEDLINE]Related articles

    7.

    Immunologic and virologic consequences of temporary antiretroviral treatment interruption in clinical practice.

    Chen RY, Westfall AO, Raper JL, Cloud GA, Chatham AK, Acosta EP, Pham SV, Tolson JM, Heudebert GR, Saag MS.

    AIDS Res Hum Retroviruses. 2002 Sep 1;18(13):909-16.PMID: 12230934 [PubMed - indexed for MEDLINE]Related articles

    8.

    Increased soluble Fas in HIV-infected hemophilia patients with CD4+ and CD8+ cell count increases and viral load and immune complex decreases.

    Daniel V, Süsal C, Weimer R, Zimmermann R, Huth-Kühne A, Opelz G.

    AIDS Res Hum Retroviruses. 2001 Mar 1;17(4):329-35.PMID: 11242519 [PubMed - indexed for MEDLINE]Related articles

    9.

    Immunological responses and long-term treatment interruption after human immunodeficiency virus type 1 (HIV-1) lipopeptide immunization of HIV-1-infected patients: the LIPTHERA study.

    Pialoux G, Quercia RP, Gahery H, Daniel N, Slama L, Girard PM, Bonnard P, Rozenbaum W, Schneider V, Salmon D, Guillet JG.

    Clin Vaccine Immunol. 2008 Mar;15(3):562-8. Epub 2008 Jan 9.PMID: 18184824 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Analyses of HIV-1 drug-resistance profiles among infected adolescents experiencing delayed antiretroviral treatment switch after initial nonsuppressive highly active antiretroviral therapy.

    Agwu A, Lindsey JC, Ferguson K, Zhang H, Spector S, Rudy BJ, Ray SC, Douglas SD, Flynn PM, Persaud D; Pediatric AIDS Clinical Trials Group 381 Study Team.

    AIDS Patient Care STDS. 2008 Jul;22(7):545-52.PMID: 18479228 [PubMed - indexed for MEDLINE]Related articles

    11.

    Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.

    Hoen B, Cooper DA, Lampe FC, Perrin L, Clumeck N, Phillips AN, Goh LE, Lindback S, Sereni D, Gazzard B, Montaner J, Stellbrink HJ, Lazzarin A, Ponscarme D, Staszewski S, Mathiesen L, Smith D, Finlayson R, Weber R, Wegmann L, Janossy G, Kinloch-de Loes S; QUEST Study Group.

    Clin Infect Dis. 2007 Aug 1;45(3):381-90. Epub 2007 Jun 26.PMID: 17599319 [PubMed - indexed for MEDLINE]Related articles

    12.

    Discordant outcomes following failure of antiretroviral therapy are associated with substantial differences in human immunodeficiency virus-specific cellular immunity.

    Price DA, Scullard G, Oxenius A, Braganza R, Beddows SA, Kazmi S, Clarke JR, Johnson GE, Weber JN, Phillips RE.

    J Virol. 2003 May;77(10):6041-9.PMID: 12719595 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia.

    Deeks SG, Barbour JD, Grant RM, Martin JN.

    AIDS. 2002 Jan 25;16(2):201-7.PMID: 11807304 [PubMed - indexed for MEDLINE]Related articles

    14.

    Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study).

    Castagna A, Danise A, Menzo S, Galli L, Gianotti N, Carini E, Boeri E, Galli A, Cernuschi M, Hasson H, Clementi M, Lazzarin A.

    AIDS. 2006 Apr 4;20(6):795-803.PMID: 16549962 [PubMed - indexed for MEDLINE]Related articles

    15.

    Immune restoration in HIV-positive, antiretroviral-naive patients after 1 year of zidovudine/lamivudine plus nelfinavir or nevirapine.

    Plana M, Ferrer E, Martínez C, Podzamczer D, García F, Maleno MJ, Barceló JJ, García A, Barberá MJ, Lacarcel M, Miró JM, Gallart T, Gatell JM.

    Antivir Ther. 2004 Apr;9(2):197-204.PMID: 15134181 [PubMed - indexed for MEDLINE]Related articles

    16.

    Lamivudine and indinavir/ritonavir maintenance therapy in highly pretreated HIV-infected patients (Vista ANRS 109).

    Launay O, Duval X, Dalban C, Descamps D, Peytavin G, Certain A, Mouajjah S, Ralaimazava P, Verdon R, Costagliola D, Clavel F; ANRS 109 VISTA Study Group.

    Antivir Ther. 2006;11(7):889-99.PMID: 17302251 [PubMed - indexed for MEDLINE]Related articles

    17.

    Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes.

    Nachega JB, Hislop M, Dowdy DW, Chaisson RE, Regensberg L, Maartens G.

    Ann Intern Med. 2007 Apr 17;146(8):564-73.PMID: 17438315 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    [Structured therapeutic interruption in patients infected with HIV-1 experiencing a block in their antiretroviral treatment: preliminary results]

    Rey D, Schmitt MP, Hess-Kempf G, Krantz V, Partisani M, Bernard-Henry C, Lang JM.

    Pathol Biol (Paris). 2001 Sep;49(7):559-66. French. PMID: 11642019 [PubMed - indexed for MEDLINE]Related articles

    19.

    Safety and factors predicting the duration of first and second treatment interruptions guided by CD4+ cell counts in patients with chronic HIV infection.

    Boschi A, Tinelli C, Ortolani P, Arlotti M.

    J Antimicrob Chemother. 2006 Mar;57(3):520-6. Epub 2005 Dec 30.PMID: 16387747 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    Baseline CD4(+) cell count, not viral load, correlates with virologic suppression induced by potent antiretroviral therapy.

    Skowron G, Street JC, Obee EM.

    J Acquir Immune Defic Syndr. 2001 Dec 1;28(4):313-9.PMID: 11707666 [PubMed - indexed for MEDLINE]Related articles

    Display Settings:

    Format
    Items per page
    Sort by

    Send to:

    Choose Destination

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity